(Q43003099)

12 November 2017

A Phase II, open-label study evaluating pazopanib in patients with recurrent ovarian cancer (English)

1 reference

12 November 2017

1 reference

3

Danny Rischin

1 reference

12 November 2017

Michael Friedlander

1

1 reference

12 November 2017

Kenneth C Hancock

2

1 reference

12 November 2017

Mark J Messing

4

1 reference

12 November 2017

Claude A Stringer

5

1 reference

12 November 2017

Gemma M Matthys

6

1 reference

12 November 2017

Bo Ma

7

1 reference

12 November 2017

Jeffrey P Hodge

8

1 reference

12 November 2017

Joanne J Lager

9

1 reference

12 November 2017

language of work or name

English

0 references

publication date

27 June 2010

1 reference

12 November 2017

1 reference

12 November 2017

119

1 reference

12 November 2017

1

1 reference

12 November 2017

32-37

1 reference

12 November 2017

Cancer statistics, 2008

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.05.033

Moderate progress for ovarian cancer in the last 20 years: prolongation of survival, but no improvement in the cure rate.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.05.033

Exploratory phase III study of paclitaxel and cisplatin versus paclitaxel and carboplatin in advanced ovarian cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.05.033

Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.05.033

Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.05.033

First line chemotherapy with carboplatin plus paclitaxel in advanced ovarian cancer--a new standard of care?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.05.033

Ovarian cancer: a focus on management of recurrent disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.05.033

Cytoreductive surgery for recurrent ovarian cancer: a meta-analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.05.033

Comparison of CA-125 and standard definitions of progression of ovarian cancer in the intergroup trial of cisplatin and paclitaxel versus cisplatin and cyclophosphamide

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.05.033

Epithelial ovarian carcinoma: ESMO clinical recommendations for diagnosis, treatment and follow-up

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.05.033

Use of CA-125 to Assess Response to New Agents in Ovarian Cancer Trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.05.033

Re: new guidelines to evaluate the response to treatment in solid tumors [ovarian cancer]. Gynecologic Cancer Intergroup

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.05.033

Relapsed ovarian cancer: challenges and management strategies for a chronic disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.05.033

Correlation of epidermal growth factor receptor expression with tumor microdensity vessels and with vascular endothelial growth factor expression in ovarian carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.05.033

Expression of vascular endothelial growth factor (VEGF) in epithelial ovarian neoplasms: correlation with clinicopathology and patient survival, and analysis of serum VEGF levels

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.05.033

Serum vascular endothelial growth factor in epithelial ovarian neoplasms: correlation with patient survival.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.05.033

Quantification of angiogenesis by the Chalkley method and its prognostic significance in epithelial ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.05.033

Role of vascular endothelial growth factor in ovarian cancer: inhibition of ascites formation by immunoneutralization

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.05.033

Pazopanib: a novel multitargeted tyrosine kinase inhibitor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.05.033

Phase I trial of pazopanib in patients with advanced cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.05.033

Planned versus attained design in phase II clinical trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.05.033

Re: New guidelines to evaluate the response to treatment in solid tumors (ovarian cancer).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.05.033

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.05.033

Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.05.033

Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.05.033

Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: a trial of the California, Chicago, and Princess Margaret Hospital phase II consortia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.05.033

Efficacy and safety of bevacizumab plus erlotinib for patients with recurrent ovarian, primary peritoneal, and fallopian tube cancer: a trial of the Chicago, PMH, and California Phase II Consortia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.05.033

Sorafenib in advanced clear-cell renal-cell carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.05.033

Sunitinib versus interferon alfa in metastatic renal-cell carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.05.033

Lack of reliability of CA125 response criteria with anti-VEGF molecularly targeted therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.05.033

Lack of reliability of CA125 response criteria with anti-VEGF molecularly targeted therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.05.033

Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.05.033

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.05.033

Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.05.033

Cediranib, an oral inhibitor of vascular endothelial growth factor receptor kinases, is an active drug in recurrent epithelial ovarian, fallopian tube, and peritoneal cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.05.033

10.1016/J.YGYNO.2010.05.033

7 January 2021

Identifiers

DOI

1 reference

12 November 2017

1 reference